Tuesday Features

enGene initiates $20 million financing to advance lead product

Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy platform to treat ulcerative colitis, a major subtype of Inflammatory Bowel Disease (IBD). Dr. Anthony Cheung “We have built significant momentum for the... [Read more of this feature]

---

Alitair builds value without outside investors

Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory therapeutics and a drug safety technology: make some money first and then go out and get investors. Dr. William W. Howard “We’ve been able to develop... [Read more of this feature]

---

Novadaq partnering strategy hits marketing milestone

Novadaq Technologies (TSX:NDQ), a maker of real-time fluorescence imaging products for the operating room, reached a significant milestone earlier this month when it named MAQUET Cardiovascular as the exclusive distributor of its CO2 Heart Laser system in the U.S. Dr. Arun Menawat “We have now completed our strategic agenda of partnering each one... [Read more of this feature]

---

More Posts From Tuesday Features

Briefs

pSivida CEO to participate at glaucoma conference

pSivida CEO Paul Ashton pSivida (NASDAQ:PSDV; ASX:PVA) CEO Dr. Paul Ashton will participate today in a panel: New Horizons in Glaucoma Drug Delivery and IOP Monitoring during the Glaucoma 360 New Horizons forum at the Palace Hotel in San Francisco. The conference is being presented by the Glaucoma Research Foundation in association with Ophthalmology... [Read more of this brief]

---

Rodman to launch automated electronic transaction platform

Rodman & Renshaw Capital Group (NASDAQ:RODM), via a new subsidiary, DirectMarkets, has unveiled an automated, state-of-the-art electronic transaction platform to directly link existing public company issuers and investors seeking to transact primary offerings of securities. Both investors and issuers will benefit from 24/7 seamless access to DirectMarkets’... [Read more of this brief]

---

Navidea to seek approval for Lymphoseek in Europe

Navidea Biopharmaceuticals (AMEX:NAVB) intends to file a Marketing Authorization Application (MAA) in the EU for Lymphoseek, its radioactive diagnostic tracing agent, based on clinical data accumulated from completed pivotal studies and supporting clinical literature. Navidea also has been advised by the European Medicines Agency’s (EMA) Committee... [Read more of this brief]

---

Roth upgrades Antares Pharma to buy

Roth Capital Partners has upgraded Antares Pharma (AMEX:AIS) to “buy” from “neutral” and raised its 12-month price target to $3.50 from $2, saying the balance sheet is strong and the company could become cash flow positive this year. “The solid financial position, platform opportunities, and potential for advancement of... [Read more of this brief]

---

Isotechnika ends existing license accord with ILJIN

Isotechnika Pharma (TSX:ISA) has exercised its right to terminate an existing development, distribution and license agreement with ILJIN Life Science of South Korea and is pursuing discussions to potentially change the current relationship with ILJIN in order to better advance its voclosporin program. Isotechnika's voclosporin is a potential breakthrough... [Read more of this brief]

---

More Posts From Briefs